Furster C
Department of Pharmaceutical Biosciences, University of Uppsala, Sweden.
Biochim Biophys Acta. 1999 Jan 4;1436(3):343-53. doi: 10.1016/s0005-2760(98)00126-x.
Conversion of 5-cholestene-3 beta,7 alpha-diol (7 alpha-hydroxycholesterol) into 7 alpha-hydroxy-4-cholesten-3-one was studied with microsomes from different pig tissues and with liver subcellular fractions. Dehydrogenase/isomerase activity was efficient in microsomes from liver, ovary and lung, but less efficient in microsomes from adrenal gland and kidney. Microsomes from these tissues, with the exception of lung, were also active in dehydrogenation/isomerization of dehydroepiandrosterone and pregnenolone. Inhibition studies were carried out with trilostane, a competitive inhibitor of 3 beta-hydroxysteroid dehydrogenases active in steroid hormone biosynthesis (C19/C21-dehydrogenases), and a monoclonal antibody raised against a purified hepatic 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase. The results showed that the C27-dehydrogenase activity in the tissues was not dependent on the C19/C21 dehydrogenases, but was dependent on the 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase. Liver mitochondria, cytosol and peroxisomes lacked dehydrogenase/isomerase activity towards 7 alpha-hydroxycholesterol when microsomal contamination was taken into account. Immunoblotting experiments with monoclonal antibodies raised against the 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase showed immunoreactivity only with protein in liver microsomes. Immunohistochemical studies showed localization of the 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase in the bile duct epithelium. It is concluded that 7 alpha-hydroxycholesterol is converted into 7 alpha-hydroxy-4-cholesten-3-one by the microsomal 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase in liver and extrahepatic tissues.
利用来自不同猪组织的微粒体以及肝脏亚细胞组分,研究了5-胆甾烯-3β,7α-二醇(7α-羟基胆固醇)向7α-羟基-4-胆甾烯-3-酮的转化。脱氢酶/异构酶活性在来自肝脏、卵巢和肺的微粒体中效率较高,但在来自肾上腺和肾脏的微粒体中效率较低。除肺外,这些组织的微粒体对脱氢表雄酮和孕烯醇酮的脱氢/异构化也有活性。使用曲洛司坦(一种在类固醇激素生物合成中具有活性的3β-羟基类固醇脱氢酶(C19/C21脱氢酶)的竞争性抑制剂)和针对纯化的肝脏3β-羟基-δ5-C27-类固醇脱氢酶产生的单克隆抗体进行了抑制研究。结果表明,组织中的C27-脱氢酶活性不依赖于C19/C21脱氢酶,而是依赖于3β-羟基-δ5-C27-类固醇脱氢酶。考虑到微粒体污染时,肝脏线粒体、胞质溶胶和过氧化物酶体对7α-羟基胆固醇缺乏脱氢酶/异构酶活性。用针对3β-羟基-δ5-C27-类固醇脱氢酶产生的单克隆抗体进行的免疫印迹实验表明,仅与肝脏微粒体中的蛋白质有免疫反应性。免疫组织化学研究表明,3β-羟基-δ5-C27-类固醇脱氢酶定位于胆管上皮。结论是,7α-羟基胆固醇在肝脏和肝外组织中通过微粒体3β-羟基-δ5-C27-类固醇脱氢酶转化为7α-羟基-4-胆甾烯-3-酮。